Patient leaflet - Giotrif 30 mg film-coated tablets
1. What GIOTRIF is and what it is used for 2. What you need to know before you take
GIOTRIF
- 3. How to take GIOTRIF
- 4. Possible side effects
- 5. How to store GIOTRIF
- 6.
information
- 1. What GIOTRIF is and what it is used for
GIOTRIF is a medicine which contains the active substance afatinib. It works by blocking the activity of a group of proteins called the ErbB family (including EGFR [epidermal growth factor receptor or ErbB1], HER2 [ErbB2], ErbB3 and ErbB4). These proteins are involved in the growth and spread of cancer cells, and can be affected by changes (mutations) in the genes that produce them. By blocking the activity of these proteins this medicine can inhibit growth and spread of cancer cells.
This medicine is used on its own to treat adult patients with a specific type of cancer of the lung (non-small cell lung cancer):
that is identified by a change
(mutation) in the gene for EGFR. GIOTRIF can be prescribed to you as your first treatment or if prior chemotherapy treatment has been insufficient.
of squamous type if prior
chemotherapy treatment has been insufficient.
2. What you need to know before you take GIOTRIF
Do not take GIOTRIF
if you are allergic to afatinib or any of the
other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor or pharmacist before taking this medicine:
if you are female, have a low body
weight of less than 50 kg or have kidney problems. If any of these apply to you, your doctor may monitor you more closely as the side effects may be more pronounced. Package leaflet: Information for the patient UK6280229P99-A1.0
GIOTRIF® 30 mg film-coated tablets
(afatinib)
Procured from within the EU and repackaged for the PL Holder:
Abacus Medicine Ltd., Abbey House, 282 Farnborough Road, Farnborough, GU14 7NA,
United Kingdom
Manufacturer
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
D-55216 Ingelheim am Rhein
Germany
PL 45763/0677
POM
GIOTRIF® is a registered trademark of Boehringer Ingelheim International GmbH
For any information about this medicine, please contact the local representative of the Product Licence Holder:
Abacus Medicine Ltd.
tel: +44(0)2036301244
email: MedInfo@abacusmedicine.co.uk or drugsafetyuk@abacusmedicine.co.uk
This leaflet was last approved on 13.02.2025.
Blind or partially sighted? Is this leaflet hard to see or read? Call 02036301310 or write to
info@abacusmedicine.com to obtain the leaflet in a format suitable for you.
Verapamil, quinidine, amiodarone -
used to treat heart conditions. • Cyclosporine A, tacrolimus -
medicines that affect your immune system.
The following medicines may reduce the effectiveness of GIOTRIF:
Carbamazepine, phenytoin,
phenobarbital - used to treat seizures.
St. John’s wort (Hypericum
perforatum), a herbal medicine to treat depression.
Rifampicin, an antibiotic used to
treat tuberculosis.
Ask your doctor if you are unsure of when to take these medicines.
GIOTRIF may increase the blood levels of other medicines including but not limited to:
Sulfasalazine, used to treat
inflammation/infection.
Rosuvastatin, used for lowering
cholesterol.
Tell your doctor before taking these medicines together with GIOTRIF.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
You should avoid becoming pregnant while taking this medicine. If you could become pregnant, you should use adequate birth control methods during treatment and for at least 1 month after taking the last dose of this medicine. This is because there may be a risk that an unborn baby is harmed.
If you become pregnant while receiving this medicine, you should immediately inform your doctor. Your doctor will decide with you whether treatment should be continued or not.
If you plan to become pregnant after taking the last dose of this medicine, you should ask your doctor for advice as your body may not have fully eliminated this medicine.
Breast-feeding
Do not breast-feed while taking this medicine as a risk to the breast-fed child cannot be excluded.
Driving and using machines
If you experience treatment-related symptoms affecting your eye sight (e.g. redness and/or irritation of the eye, dry eye, tearing, light-sensitivity) or your ability to concentrate and react, it is recommended that you do not drive or use machines until the side effect disappears (see section 4 Possible side effects).
GIOTRIF contains lactose
This medicine contains a sugar called lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
3. How to take GIOTRIF
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Dosage
The recommended dose is 40 mg each day.
Your doctor may adjust (increase or decrease) your dose depending on how well you tolerate this medicine.
When to take GIOTRIF
It is important to take this medicine
without food
Take this medicine at least 1 hour
before eating,
or
If you have already eaten, wait at
least 3 hours before taking this medicine.
Take this medicine once daily about
the same time each day. This makes it easier to remember to take this medicine.
Do not break, chew or crush the
tablet.
Swallow the tablet whole with a
glass of still water.
GIOTRIF is to be taken by mouth. If you have difficulties swallowing the tablet, dissolve it in a glass of still water. No other liquids should be used. Drop the tablet into the water without crushing it, and occasionally stir for up to 15 min until the tablet is broken up into very small particles. Drink the liquid straight away.
Then fill the glass again with water and drink it to make sure all medicine is taken.
If you are not able to swallow and have a gastric tube your doctor might suggest that the medicine is given to you via the tube.
If you take more GIOTRIF than you should
Contact your doctor or pharmacist immediately. You may experience increased side effects and your doctor may interrupt your treatment and provide supportive care.
If you forget to take GIOTRIF
If your next scheduled dose is more than 8 hours away, take the missed dose as soon as you remember.
If your next scheduled dose is due within 8 hours, skip the missed dose and take your next dose at the usual time. Then carry on taking your tablets at regular times as usual.
Do not take a double dose (two tablets instead of one at the same time) to make up for a missed dose.
If you stop taking GIOTRIF
Do not stop taking this medicine without first consulting your doctor. It is important to take this medicine every day, as long as your doctor prescribes it for you. If you do not take this medicine as prescribed by your doctor your cancer may grow again.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, GIOTRIF can cause side effects, although not everybody gets them.
Contact your doctor as soon as possible if you suffer from any of the serious side effects listed below. In some cases your doctor may need to interrupt treatment and reduce your dose or stop treatment:
Diarrhoea (very common, may
affect more than 1 in 10 people). Diarrhoea lasting more than 2 days or more severe diarrhoea may lead to fluid loss (common, may affect up to 1 in 10 people), low blood
potassium (common) and worsening kidney function (common). Diarrhoea can be treated. At the first signs of diarrhoea drink plenty of fluids. Contact your doctor immediately and start appropriate antidiarrhoeal treatment as soon as possible. You should have antidiarrhoeal medicine available prior to taking GIOTRIF.
Skin rash (very common).
It is important to treat the rash early. Tell your doctor if a rash starts. If treatment for rash is not working and the rash is getting more severe (for example, you have peeling or blistering of the skin) you should notify your doctor immediately, since your doctor may decide to stop your treatment with GIOTRIF. Rash may occur or worsen in areas exposed to sun. Sun protection with protective clothing and sunscreen is recommended.
Inflammation of the lungs
(uncommon, may affect up to 1 in 100 people)called “interstitial lung disease”. Tell your doctor immediately if you develop new or sudden worsening of shortness of breath, possibly with a cough or fever.
Eye irritation or inflammation
Eye irritation or inflammation may occur (conjunctivitis/dry eye occurs commonly and keratitis uncommonly). Tell your doctor if you have sudden or worsening of eye symptoms such as pain or redness or dry eye.
If you experience any of the symptoms above, contact your doctor as soon as possible.
The following other side effects have also been reported:
Very common side effects
(may affect more than 1 in 10 people):
- Mouth sores and inflammation • Nail infection
- Decreased appetite
- Bleeding from the nose
- Nausea
- Vomiting
- Itching
- Dry skin
Common side effects
(may affect up to 1 in 10 people):
Pain, redness, swelling or peeling of
the skin of your hands and feet • Increased levels of the
liver enzymes (aspartate
aminotransferase and alanine aminotransferase) in blood tests. • Inflammation of the lining of the
bladder with burning sensations during urination and frequent, urgent need to urinate (cystitis)
Abnormal taste sensations
(dysgeusia)
Stomach pain, indigestion,
heartburn
- Lip inflammation
- Decreased weight
- Runny nose
- Muscle spasms
- Fever
Nail problems
Uncommon side effects
(may affect up to 1 in 100 people):
Inflammation of the pancreas
(pancreatitis)
- Occurrence of a tear in the wall of your stomach or intestines (gastrointestinal perforation)
Rare side effects (may affect up to 1 in 1,000 people):
Severe blistering or peeling of skin
(suggestive of Stevens-Johnson syndrome and toxic epidermal necrolysis)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed on this leaflet. You can also report side effects directly via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
5. How to store GIOTRIF
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, the pouch and the blister after EXP. The expiry date refers to the last day of that month.
Store in the original package in order to protect from moisture and light.
If your medicine shows any signs of discolouration or deterioration, you should seek the advice of your pharmacist.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
6. Contents of the pack and other information
What GIOTRIF contains
- The active substance is afatinib. Each film-coated tablet contains 30 mg of afatinib (as dimaleate).
- The other ingredients are lactose monohydrate, microcrystalline cellulose (E460), colloidal anhydrous silica (E551), crospovidone type A, magnesium stearate (E470b), hypromellose (E464), macrogol 400, titanium dioxide (E171), talc (E553b), polysorbate 80 (E433), indigo carmine (E132) aluminium lake.
What GIOTRIF looks like and contents of the pack
GIOTRIF 30 mg film-coated tablets are dark blue and round shaped. They are debossed with the code “T30” on one side and the Boehringer Ingelheim company logo on the other.
GIOTRIF film-coated tablets are in packs containing 4 perforated unit dose blisters. Each blister contains 7 x 1 film-coated tablets and is packed in an aluminium pouch together with a desiccant sachet that should not be swallowed.